Diaxonhit Stock Euronext Paris
Equities
FR0004054427
Biotechnology & Medical Research
Sales 2023 | 130M 141M 192M | Sales 2024 * | 138M 150M 204M | Capitalization | 148M 161M 219M |
---|---|---|---|---|---|
Net income 2023 | 4M 4.35M 5.91M | Net income 2024 * | 9M 9.78M 13.3M | EV / Sales 2023 | 1.29 x |
Net Debt 2023 * | 23M 25M 34M | Net cash position 2024 * | 9.9M 10.76M 14.64M | EV / Sales 2024 * | 1 x |
P/E ratio 2023 |
38.3
x | P/E ratio 2024 * |
15.3
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 61.3% |
Managers | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 17-06-18 |
Director of Finance/CFO | 43 | 22-09-30 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 17-06-18 |
Director/Board Member | 68 | 09-11-03 | |
Director/Board Member | 67 | 17-06-14 |
1st Jan change | Capi. | |
---|---|---|
+28.88% | 49.18B | |
+0.86% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.18% | 18.71B | |
+7.85% | 13.26B | |
+32.41% | 12.32B | |
-0.63% | 11.99B |